ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings
© 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition..
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide, with more than three million viraemic adolescents and children. Treatment of adults with HCV infection and HCV-related liver disease has advanced considerably thanks to development and improvements in therapy. Direct-acting antiviral regimens are safe and effective. Three regimens with pangenotypic activity (glecaprevir/pibrentasvir, sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir) and three regimens with genotype-specific activity (sofosbuvir/ribavirin, sofosbuvir/ledipasvir and elbasvir/grazoprevir) have been approved with age-specific limitation for treatment of children with chronic hepatitis C by the European Medicines Agency and the United States Food and Drug Administration. The World Health Organization has set the ambitious target to eliminate hepatitis C as a major public health threat by 2030 and based its actions against HCV on the large use of direct acting antivirals. These updated European Society for Pediatric Gastroenterology, Hepatology and Nutrition recommendations on treatment of hepatitis C describe the optimal therapeutic management of adolescents and children with HCV infection including specific indications for those living in resource-limited settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Journal of pediatric gastroenterology and nutrition - 78(2024), 4 vom: 11. Apr., Seite 957-972 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Indolfi, Giuseppe [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.04.2024 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jpn3.12160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368599507 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368599507 | ||
| 003 | DE-627 | ||
| 005 | 20240410232531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240219s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jpn3.12160 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM368599507 | ||
| 035 | |a (NLM)38369891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Indolfi, Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. | ||
| 520 | |a Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide, with more than three million viraemic adolescents and children. Treatment of adults with HCV infection and HCV-related liver disease has advanced considerably thanks to development and improvements in therapy. Direct-acting antiviral regimens are safe and effective. Three regimens with pangenotypic activity (glecaprevir/pibrentasvir, sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir) and three regimens with genotype-specific activity (sofosbuvir/ribavirin, sofosbuvir/ledipasvir and elbasvir/grazoprevir) have been approved with age-specific limitation for treatment of children with chronic hepatitis C by the European Medicines Agency and the United States Food and Drug Administration. The World Health Organization has set the ambitious target to eliminate hepatitis C as a major public health threat by 2030 and based its actions against HCV on the large use of direct acting antivirals. These updated European Society for Pediatric Gastroenterology, Hepatology and Nutrition recommendations on treatment of hepatitis C describe the optimal therapeutic management of adolescents and children with HCV infection including specific indications for those living in resource-limited settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a position paper | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a virological response | |
| 650 | 7 | |a Sofosbuvir |2 NLM | |
| 650 | 7 | |a WJ6CA3ZU8B |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a velpatasvir |2 NLM | |
| 650 | 7 | |a KCU0C7RS7Z |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 650 | 7 | |a Benzopyrans |2 NLM | |
| 650 | 7 | |a Carbamates |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 4 or More Rings |2 NLM | |
| 700 | 1 | |a Gonzalez-Peralta, Regino P |e verfasserin |4 aut | |
| 700 | 1 | |a Jonas, Maureen M |e verfasserin |4 aut | |
| 700 | 1 | |a Sayed, Manal Hamdy-El |e verfasserin |4 aut | |
| 700 | 1 | |a Fischler, Björn |e verfasserin |4 aut | |
| 700 | 1 | |a Sokal, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Wirth, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Nicastro, Emanuele |e verfasserin |4 aut | |
| 700 | 0 | |a Hepatology Committee of the ESPGHAN |e verfasserin |4 aut | |
| 700 | 1 | |a Kohlmaier, Benno |e investigator |4 oth | |
| 700 | 1 | |a Fitzpatrick, Emer |e investigator |4 oth | |
| 700 | 1 | |a Gonzales, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Junge, Norman |e investigator |4 oth | |
| 700 | 1 | |a Mancell, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Mozer-Glassberg, Yael |e investigator |4 oth | |
| 700 | 1 | |a Pop, Tudor |e investigator |4 oth | |
| 700 | 1 | |a Samyn, Marianne |e investigator |4 oth | |
| 700 | 1 | |a Stephenne, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Zellos, Aglaia |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pediatric gastroenterology and nutrition |d 1982 |g 78(2024), 4 vom: 11. Apr., Seite 957-972 |w (DE-627)NLM012621927 |x 1536-4801 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2024 |g number:4 |g day:11 |g month:04 |g pages:957-972 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jpn3.12160 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2024 |e 4 |b 11 |c 04 |h 957-972 | ||